Retatrutide in Colombia

Retatrutide Colombia: Evidence and Documented RUO Material

Retatrutide, also known as LY3437943, is an investigational molecule that activates the GIP, GLP-1, and glucagon receptors. Because of this mechanism, it is described as a triple receptor agonist. Although clinical results are available, retatrutide is not currently an approved medicine.

In the Phase 2 trial by Jastreboff and colleagues, the retatrutide 12 mg arm showed a mean body-weight change of -24.2% at 48 weeks, compared with -2.1% with placebo. This figure applies specifically to the 12 mg study arm and is not the average result for the entire trial. The study enrolled 338 adults and also reported dose-related gastrointestinal adverse events and increases in heart rate.

Scientific source: Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2301972. PubMed: https://pubmed.ncbi.nlm.nih.gov/37366315/

For people searching for Retatrutide in Colombia, it is important to separate clinical evidence from the analytical documentation of RUO material. A Certificate of Analysis may provide information about the identity and purity of a sample, but it does not establish efficacy, sterility, clinical safety, or pharmaceutical equivalence.

Retatrutide RUO at Peptilab

Peptilab.co is a Colombian experimental biotechnology portal that publishes scientific information and batch-specific documentation. Its Retatrutide listing provides access to:

The vials are offered exclusively as research materials under the RUO classification, meaning Research Use Only. Orders include 3 ml of bacteriostatic water, alcohol swabs, and a reconstitution guide. Syringes are not included. The current batch, price, availability, and estimated delivery time are confirmed before the order is coordinated through WhatsApp.

Retatrutide Colombia listing: https://peptilab.co/tienda/metabolico/retatrutida/

Notice: exclusively for research use. This material is not a medicine, is not intended for human use, and this information does not constitute medical advice or a treatment recommendation.